Starling Oncology, Inc.

NasdaqCM:STLN Stock Report

Market Cap: US$523.4m

Starling Oncology Future Growth

Future criteria checks 2/6

Starling Oncology is forecast to grow earnings and revenue by 103.4% and 22.9% per annum respectively while EPS is expected to grow by 117.7% per annum.

Key information

103.4%

Earnings growth rate

117.69%

EPS growth rate

Healthcare earnings growth18.5%
Revenue growth rate22.9%
Future return on equityn/a
Analyst coverage

Low

Last updated09 Jul 2026

Recent future growth updates

Analysis Article • May 11

The Oncology Institute, Inc. (NASDAQ:TOI) Analysts Are Pretty Bullish On The Stock After Recent Results

As you might know, The Oncology Institute, Inc. ( NASDAQ:TOI ) just kicked off its latest first-quarter results with...

Recent updates

Narrative Update • Jul 21

TOI: Index Additions And 2026 Guidance Will Support Bullish Repricing

Analysts have raised their fair value estimate for Oncology Institute from $8.00 to $10.00, citing revised assumptions for revenue growth, profit margins, the discount rate, and a substantially higher future P/E multiple in their updated price target analysis. What’s in the News for Oncology Institute Oncology Institute was added to the Russell Small Cap Comp Value Benchmark, according to index constituent updates.
Narrative Update • Jul 07

TOI: Index Additions And 2026 Guidance Will Support Future Upside Potential

Analysts have raised their fair value estimate for Oncology Institute from $5.00 to $7.00, citing updated assumptions for revenue growth, profit margins, a higher future P/E multiple, and a slightly higher discount rate. What's in the News Oncology Institute was added to the Russell Microcap Value Benchmark Index, according to index constituent change data.
Narrative Update • Jun 23

TOI: Reaffirmed 2026 Revenue Outlook Will Support Higher Forward Earnings Power

Analysts have raised their price target for Oncology Institute to $7.75 from $7.00, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple in their valuation work. What’s in the News for Oncology Institute Oncology Institute reaffirmed earnings guidance for fiscal 2026, keeping anticipated total revenue in the range of $630 million to $650 million.
Analysis Article • May 11

The Oncology Institute, Inc. (NASDAQ:TOI) Analysts Are Pretty Bullish On The Stock After Recent Results

As you might know, The Oncology Institute, Inc. ( NASDAQ:TOI ) just kicked off its latest first-quarter results with...
Analysis Article • Feb 02

Investors Give The Oncology Institute, Inc. (NASDAQ:TOI) Shares A 26% Hiding

Unfortunately for some shareholders, the The Oncology Institute, Inc. ( NASDAQ:TOI ) share price has dived 26% in the...
Seeking Alpha • Dec 18

The Oncology Institute: Making Progress

Summary The Oncology Institute recently achieved its first profitable Adj. EBITDA for the month and posted 37% YoY revenue growth, beating consensus by $13.9M. TOI raised FY25 guidance to $500M revenue and expects positive Adj. EBITDA in Q4, with cash flow positivity likely by mid-2026. Despite a massive share price surge in 12 months, GAAP EPS profitability remains two years away; consolidation is expected before a favorable entry point. An analysis of The Oncology Institute follows in the paragraphs below. Read the full article on Seeking Alpha
Analysis Article • Nov 22

Investors Give The Oncology Institute, Inc. (NASDAQ:TOI) Shares A 29% Hiding

The Oncology Institute, Inc. ( NASDAQ:TOI ) shareholders won't be pleased to see that the share price has had a very...
Analysis Article • Sep 11

Market Cool On The Oncology Institute, Inc.'s (NASDAQ:TOI) Revenues Pushing Shares 26% Lower

The Oncology Institute, Inc. ( NASDAQ:TOI ) shares have retraced a considerable 26% in the last month, reversing a fair...
Analysis Article • Jul 15

The Oncology Institute, Inc. (NASDAQ:TOI) Stock Rockets 30% But Many Are Still Ignoring The Company

The Oncology Institute, Inc. ( NASDAQ:TOI ) shares have continued their recent momentum with a 30% gain in the last...
User avatar
New Narrative • Jun 02

Value Based Care Contracts Will Unlock Future Oncology Demand

New value-based care contracts and expanded partnerships are driving sustained growth and enhancing recurring revenue in a shifting oncology market.
Analysis Article • Apr 18

A Piece Of The Puzzle Missing From The Oncology Institute, Inc.'s (NASDAQ:TOI) 161% Share Price Climb

The Oncology Institute, Inc. ( NASDAQ:TOI ) shares have continued their recent momentum with a 161% gain in the last...
Analysis Article • Mar 04

Market Cool On The Oncology Institute, Inc.'s (NASDAQ:TOI) Revenues Pushing Shares 28% Lower

The Oncology Institute, Inc. ( NASDAQ:TOI ) shares have retraced a considerable 28% in the last month, reversing a fair...
Analysis Article • Jan 18

The Oncology Institute, Inc. (NASDAQ:TOI) Stock Rockets 195% But Many Are Still Ignoring The Company

The Oncology Institute, Inc. ( NASDAQ:TOI ) shareholders would be excited to see that the share price has had a great...
Analysis Article • Jul 19

A Piece Of The Puzzle Missing From The Oncology Institute, Inc.'s (NASDAQ:TOI) 28% Share Price Climb

The Oncology Institute, Inc. ( NASDAQ:TOI ) shareholders are no doubt pleased to see that the share price has bounced...
Analysis Article • May 05

The Oncology Institute, Inc. (NASDAQ:TOI) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Unfortunately for some shareholders, the The Oncology Institute, Inc. ( NASDAQ:TOI ) share price has dived 29% in the...
Analysis Article • Mar 21

Not Many Are Piling Into The Oncology Institute, Inc. (NASDAQ:TOI) Stock Yet As It Plummets 28%

The Oncology Institute, Inc. ( NASDAQ:TOI ) shares have had a horrible month, losing 28% after a relatively good period...
Analysis Article • Mar 05

Is Oncology Institute (NASDAQ:TOI) A Risky Investment?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Earnings and Revenue Growth Forecasts

NasdaqCM:STLN - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20281,0893N/AN/A1
12/31/2027825-5N/AN/A4
12/31/2026656-16N/AN/A5
3/31/2026546-36-26-22N/A
12/31/2025503-50-28-25N/A
9/30/2025461-55-28-24N/A
6/30/2025424-54-13-10N/A
3/31/2025403-53-19-16N/A
12/31/2024393-53-30-27N/A
9/30/2024379-57-38-35N/A
6/30/2024361-59-48-44N/A
3/31/2024343-60-40-37N/A
12/31/2023324-68-41-36N/A
9/30/2023310-61-52-46N/A
6/30/2023293-50-64-59N/A
3/31/2023274-40-67-60N/A
12/31/20222520-67-62N/A
9/30/2022233-1-75-71N/A
6/30/2022221-2-58-53N/A
3/31/20222106-54-50N/A
12/31/2021203-11-36-33N/A
9/30/2021200-6-13-10N/A
6/30/2021195-3-12-10N/A
3/31/2021192-5-11-9N/A
12/31/2020188-14-11N/A
12/31/2019155-4N/A4N/A
12/31/2018113-2N/A6N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: STLN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: STLN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: STLN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: STLN's revenue (22.9% per year) is forecast to grow faster than the US market (12.7% per year).

High Growth Revenue: STLN's revenue (22.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if STLN's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/05 03:41
End of Day Share Price 2026/08/04 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Starling Oncology, Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yuan ZhiB. Riley Securities, Inc.
David LarsenBTIG
Alexander DraperGuggenheim Securities, LLC